Form 4: Iovance Biotherapeutics Director McPeak Acquires 50,000 Deferred Restricted Stock Units

Director Merrill A. McPeak acquired 50,000 deferred restricted stock units in Iovance Biotherapeutics, Inc. on March 1, 2024.

Summary

• On March 1, 2024, Merrill A. McPeak, a director of Iovance Biotherapeutics, Inc., acquired 50,000 deferred restricted stock units (DRSUs).
• These DRSUs represent a contingent right to receive one share of Iovance's common stock each and were granted under the company's 2018 Equity Incentive Plan.
• 50% of the RSUs will vest six months after the grant date, and the remaining 50% will vest one year after the grant date.
• The issuance of the common stock will be deferred until the earlier of three months after McPeak's resignation, removal, death, or disability, a change in control, or ten years from the transaction date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating an acquisition of stock units by a director, which is generally a positive sign but doesn't provide strong directional information.

Positives

• The acquisition of deferred restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and provides limited insight into broader industry trends.

Stakeholder Impact

• The acquisition of stock units by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates